Chronic exposure to methyl tertiary butyl ether (MTBE) altered the rodent tumor incidence of endocrine-sensitive tissues and decreased the incidence of estrogen-dependent uterine cystic hyperplasia in mice. To test the hypothesis that changes in the incidence of tumors in female B6C3F1 mice after MTBE exposure are secondary to endocrine alterations, we exposed female mice to the carcinogenic dose of MTBE vapor (8000 ppm) for 3 or 21 days or 4 or 8 months under conditions similar to a previous 2-year bioassay. MTBE exposure significantly decreased body weight gain and ovary and pituitary weight at 4 and 8 months and uterine weight at all time points. After 8 months of exposure, MTBE significantly increased the length of the estrous cycle by increasing the mean number of days in both the estrus and the nonestrus stages. Histological evaluation of H&E-stained tissues showed a decrease in the number of uterine glands after subchronic MTBE exposure. DNA synthesis, as measured by the incorporation of 5-bromo-2'-deoxyuridine (BrdU), was decreased in uterine glandular and luminal epithelial cells after MTBE exposure for 3 or 21 days or 4 or 8 months. MTBE exposure decreased the number of epithelial layers in the cervix and vagina at all time points. DNA synthesis was decreased in cervical and vaginal epithelium after 21 days of MTBE. Decreased zona reticularis of adrenal glands was found after 4 and 8 months of MTBE exposure without changes in BrdU incorporation. MTBE did not competitively bind to estrogen receptor. MTBE exposure did not alter serum estrogen levels or alter the location or intensity of estrogen receptor immunoreactivity in the uterus, cervix, and vagina. These data indicate that while MTBE exposure causes multiple endocrine-related tissue and cellular responses, these effects are not mediated through the estrogen receptor.
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Methyl tertiary butyl ether (MTBE) is added to some formulations of unleaded gasoline (UG) to increase octane and decrease carbon monoxide emissions in automobile exhaust in compliance with the Clean Air Act of 1990 (Taniguchi ' Present address: Pathology Associates International, 4915D Prospectus Drive, Durham, NC 27713. and Johnson, 1979) . At least 20% of the UG sold in 1995 contained MTBE at levels ranging from 2 to 15%. In the United States, the estimated use of MTBE in 1996 is 12 million tons (Lorenzetti, 1994; Williams, 1995) . The major route of exposure to MTBE is by inhalation of vapors during the production and transportation of MTBE and during fueling with UG blends that contain MTBE (Reynolds et al., 1984; U.S. EPA, 1993) . The health risk to humans of lowdose, intermittent exposure to MTBE is unknown.
In bioassays by inhalation and gavage, MTBE modulated the rodent tumor profile of endocrine-sensitive organ systems (Burleigh-Flayer et al, 1991; Chun et al., 1992; Bepoggi et al., 1995) . MTBE significantly increased the incidence of testicular Leydig cell tumors in Sprague-Dawley and Fisher 344 rats and decreased the incidence of tumors in mammary, adrenal, and pituitary gland in female SpragueDawley rats. In addition, MTBE vapor increased the incidence of kidney tumors in male Fisher 344 rats and liver tumors in female CD-I mice. Since increased kidney tumors in male rats (Roe and Neuhaus, 1967) , liver tumors in female mice (Moser et al., 1997b) , and Leydig cell and mammary, adrenal, and pituitary gland tumors are hormonally mediated, we hypothesized that changes in the incidence of tumors after MTBE exposure were modulated by endocrine effects.
MTBE vapor-induced hormonal changes in the bioassay are further supported by a dose-dependent decrease in the incidence of uterine endometrial cystic hyperplasia in MTBE-exposed mice as compared to air-exposed controls (Burleigh-Flayer etai, 1991) . Development of uterine cystic hyperplasia is a common finding in aged mice in bioassays and under the control of estrogen secreted by the granulosa cells of ovaries (Conney et al., 1967) . Control mice had a 52% incidence of endometrial hyperplasia at 18 months whereas 3000 ppm MTBE decreased the incidence to 30%, and 8000 ppm MTBE decreased the incidence to 12%. In the bioassay, MTBE-induced effects on the uterus are suggestive of estrogen antagonism.
Estrogen mediates its effects on the uterus principally by binding to specific intracellular estrogen receptors (ER). The estrogen-ER complex binds to responsive elements of the DNA that regulate the expression of genes involved in growth and differentiation (McLachlan et ai, 1991) . The most extensively studied antiestrogens, tamoxifen and ICI 164,384, compete with endogenous estrogen for ER binding and block the actions of estrogen (Wakeling et al., 1990; Katzenellenbogen et al., 1979) . Other chemicals such as 2,3,7,8,-tetrachlorodibenzo-/?-dioxin (TCDD) and PCB77 do not competitively bind to ER, but attenuate estrogen-induced biological effects, e.g., increased uterine weight (Jansen et al., 1993; Kociba et al., 1978; Romkes et al, 1987) . Thus, the TCDD-and PCB77-induced antiestrogenic effects are not mediated through binding to ER. Whether MTBE has the ability to competitively bind to ER is unknown.
To test the hypothesis that the female mouse tumor response in the liver after MTBE exposure was associated with hormonal changes, we evaluated female mice exposed to MTBE vapor under bioassay conditions for alterations in endocrine-sensitive tissues. We demonstrated that MTBE exposure altered endocrine-sensitive end points in the uterus, cervix, vagina, and adrenal glands. To determine if ER is involved in the effects of MTBE on endocrine-sensitive tissues in the female mouse, we examined the ability of MTBE to alter serum estrogen levels, competitively bind to the ER, activate the ER in a mammalian-based transient transfection assay, and alter ER immunoreactivity. We provide evidence that MTBE-induced endocrine alterations in female mice did not occur through a mechanism mediated by ER.
MATERIALS AND METHODS
Chemicals. High-purity MTBE (CAS No. 1624-04-4, Lot No. SC940225T-59-I) (>99.95% pure) was provided by ARCO Petroleum Co. (Newton Square, PA). 17/3-[ 3 H]Estradiol was purchased from Amersham (Arlington Heights, IL) and recombinant human estrogen receptor from PanVera Corp. (Madison, WI) Monoclonal anti-5-bromo-2'-deoxyuridine (BrdU) for immunohistochemistry was purchased from Becton-Dickinson (Mountain View, CA), proliferating cellular nuclear antigen (PCNA) antibody was purchased from Signet Laboratories (Dedham MA), and ER monoclonal antibody was purchased from DAKO (Carpintena, CA). Aminoethyl carbazole and peroxidase-conjugated streptavidin were purchased from Zymed Laboratories, Inc (San Francisco, CA). Normal goat serum and biotin-conjugated anti-rabbit IgG were purchased from Vector Labs, Inc. (Burlingame, CA). Primary antibody diluting buffer was purchased from Biomeda Corp. (Foster City, CA). Trypsm was obtained from Gibco/ BRL (Grand Island, NY). All other chemicals were obtained from Sigma Chemical Co (St. Louis, MO).
Animals.
All experiments were conducted under National Institutes of Health (NIH) guidelines for the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee, Chemical Industry Institute of Toxicology (CIIT). B6C3F1 mice were bred as previously described (Burleigh-Flayer et ai. 1991) . All mice were housed in humidity-and temperature-controlled HEPA-filtered rooms in facilities accredited by the American Association of Laboratory Animal Care.
Experimental design. A one-factor (treatment), two-level design was used to evaluate the effects of MTBE exposure The number of days of MTBE exposure was blocked in these experiments The effect of MTBE exposure on body weight, absolute and relative organ weights, serum estrogen levels, and length and stage of the estrous cycle was evaluated.
Animal treatments. Beginning at 8 weeks of age, groups of 12 female B6C3F1 mice were exposed to control air or a target concentration of 8000 ppm MTBE for 4 or 8 months under bioassay conditions as previously described (Moser et ai. 1996) . Briefly, mice were housed individually in hanging stainless-steel cages contained in 1-m 3 stainless-steel and glass, whole-body inhalation chambers. Exposures were 6 h/days, 5 days/week including holidays. MTBE vapors were generated by the flow of liquid MTBE into a stainless-steel J-tube containing glass beads. The vaporized MTBE was earned by a stream of nitrogen and mixed with HEPA-filtered air before delivery to the chamber. Mice were randomized by weight before treatment by using computer-generated numerical randomization tables. The mean weight of MTBE-exposed mice at the start of exposure was 22.3 g, and the mean weight of control mice was 23.5 g at the start of the experiment. In order to isolate exposed mice from controls, MTBE-exposed mice were housed in one room and air-exposed control mice in another room. Particulate-free control air contained 0 ppm MTBE as monitored by gas chromatography analysis (Moser et ai, 1996; Moser el ai, 1997a) . Other groups of 5-6 mice were exposed to 8000 ppm MTBE for 3 or 21 days under the same exposure conditions to determine the short-term effects of MTBE exposure (Moser et ai, 1996) . Ovariectomized mice were used as estrogen-deficient control animals for histological evaluation of H&E-stained sections and BrdU, PCNA, and ER immunoreactivity. After weaning at approximately 28 days of age, mice randomly assigned by body weight were surgically ovariectomized. For bilateral ovariectomy, ovaries were visualized by a dorsal midline incision caudal to the last rib, clamped at the level of the oviducts, and excised (Moser et ai, 1997b) .
Necropsy. Mice were weighed and anesthetized with isoflurane approximately 18 h after the last exposure. The thoracic cavity was opened and blood withdrawn via cardiac puncture widi a 21-gauge needle. Mice were euthanized by exsanguination Blood was allowed to clot for a minimum of 30 min and centrifuged, and serum was stored at -70°C for estrogen analysis. Uterus, ovaries, and adrenal and pituitary glands were weighed. Ovariectomy was confirmed at the time of necropsy. Cervix, vagina, ovaries in intact mice, uterus including the uterine horn, and pituitary and adrenal glands were fixed in 10% neutral-buffered formalin for 48 h and then in 709b ethanol. Fixed tissues were processed for routine embedment in paraffin, sectioned at 5 fim, stained with hematoxylin and eosin (H&E), and examined by light microscopy.
Vaginal smears and lavages. Vaginal smears were taken at necropsy by impressing the luminal surface of incised vaginas onto a glass slide. For vaginal lavages, the vagina was flushed with two drops of physiological saline, and the fluid was aspirated back into the tip of a glass eye dropper. The flush aspirate containing cells washed from the vaginal wall was placed onto a glass slide. Both necropsy smears and vaginal lavage aspirates were air-dried, stained with Wrights-Geisma stain, and examined microscopically to determine the stage of the estrous cycle at the time the sample was taken. The predominance or relative ratio of nucleated epithelia, comified squamous epithelia, and leukocytes was used to indicate the stage of estrous as early proestrus, late proestrus, estrus, or diestrus (Moser et ai, 1997b) Duration of a complete estrous cycle was determined as the number of days from the first appearance of solely comified epithelial cells (estrus) to the reappearance of solely comified epithelial cells. Vaginal lavages were performed at approximately 7:00 AM prior to the start of exposure for at least 10 consecutive days.
Cell proliferation.
At least eight mice per group were implanted 3j days before necropsy at approximately 2:00 PM with 7-day osmotic pumps (Alzet Model 2001, 1.06 fil/h, Alza Corp., Palo Alto, CA) containing 16 mg BrdU (Sigma Chemical Co., CAS No. 59-14-3, >99% pure)/ml phosphatebuffered saline (pH 7.2) (Standeven et ai, 1994b) . Coded paraffin sections of uterus, cervix, vagina, ovaries, and adrenal and pituitary gland were immunohistochemically stained for nuclear BrdU incorporation, and proliferation was determined as cells in S phase by light microscopy with the investigator blind as to animal treatment (Standeven et ai, 1994a; Goldsworthy et ai. 1991) . To determine the approximate labeling index (LI) the approximate number of labeled and unlabeled cells of a particular type, i.e., epithelial, stromal, muscular, and reticularis, in a 40x field was determined. Approximate LI was the number of labeled cells divided by the total number of cells of the same type. A minimum of eight fields from at least three control and MTBE-exposed mice in the same stage of estrous was examined. However, since mice were not all killed at the same stage of the estrous cycle and given that there were no controls in the diestrus stage at 4 months, no comparisons were made between MTBE-exposed mice and control mice in the diestrus stage of the estrous cycle at 4 months Proliferation was also qualitatively examined after immunohistochemically staining for PCNA. PCNA is an auxiliary protein of DNA polymerase, which is synthesized during the late Gl and S phases of the cell cycle (Wasseem and Lane, 1990) . PCNA was detected as previously described (Foley et al., 1993) .
I7p-Estradiol binding competition assay.
The assay was performed as previously described by Tzukerman et. al. (1994) with slight modifications (Oburn el al., 1993) . Tenfold serial dilutions of 17/9-estradiol and MTBE were prepared in 10 mM Tris (pH 7.6), 0.3 M potassium chloride (KG), 5 mM dithiothreitol (DTT), and 1 mg/ml bovine serum albumin (BSA). 17/3-Estradiol or MTBE (100 /il) ranging in concentrations from 10~3 to 10"" M or 10* 4 to 10~" M, respectively, were transferred to a polystyrene tube n/J-pH] Estradiol (5 nM) and recombinant human ER (4.5 nM) were added to each rube After an overnight incubation at 4°C, 100 ^1 of a 6% hydroxyapatite (HAP) slurry in dilution buffer was added. Tubes were incubated at 4°C for 30 min and then centrifuged at lOOOg for 10 min. HAP pellets were washed four times with 1 ml of 1% Triton X-100 in dilution buffer and resuspended in 1 ml of dilution buffer and transferred to scintillation vials. Scintillation fluid, Ecolume (1CN, Costa Mesa, CA), was added, and vials were vortexed. Radioactivity was measured on a Packard Tri-carb 460 scintillation counter (Packard Instruments).
HepG2 transient transfection ER assay.
The method for transfection was performed as previously described (Tzukerman el al., 1994) . Briefly, cells were seeded for 18 h in 24-well plates in phenol red free Eagle's minimal essential medium with nonessential amino acids (Gibco/BRL) containing 10% resin-stripped fetal bovine serum, 2% L-glutamine, and 0.1% sodium pyruvate at a density of 2.0 X 10 3 cells per well. The cells were transfected with three plasmids: receptor plasmid at 270 ng/well, C2-LUC promoter plasmid at 405 ng/well, and ,9-Gal plasmid as a transfection control at 135 ng/well in Lipofectin and OptiMEM to a final volume of 300 ^1 for 3 h. After rinsing with phosphate-buffered saline, cells were treated as described above with various doses of estradiol, MTBE, or MTBE plus 3 X 10" 8 M estradiol in complete medium. A vehicle control of 0.1% DMSO was included. After 24 h incubation cells were lysed with buffer (25 mM Tris, pH 7.8, 2 mM l,2-diaminocyclohexane-A',A',A',A'-tetraacetic acid, 10% glycerol, 0.05% Triton-X, 2 mM DDT). Lysate was divided for luciferase and /3-galactosidase activity determination into two plates of 96 wells. For luciferase activity evaluation, 100 ml of Luciferase Assay Reagent (Promega, Madison, WI) was added to lysate and luminescence was determined using a Microlite ML3000 microtiter plate luminometer (Dynatech Laboratories, Chantilly, VA). For /J-galactosidase activity determination, 20 /il of 4 mg/ml chlorophenol red-/3-r>galactopyranoside (CPRG) and 150 fi\ CPRG buffer (6 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCI, 1 mM MgSO 4 , 50 mM /9-mercaptaoethanol; pH 7.8) were added to lysate. The absorbance at 570 nm was determined immediately on a kinetic microplate reader (Molecular Devices, Menlo Park, CA). ER activity was normalized to ^-galactosidase activity.
Serum estrogen levels. Serum 17^-estradiol levels were determined with the solid-phase radioimmunoassay Coat-a-Count Estradiol (Diagnostic Products Corp., Los Angeles, CA). The assay can detect as little as 8 pg/ml.
Estrogen receptor immunohistochemistry. ER antibody is a monoclonal mouse antibody raised against the N terminus of human ER. Paraffinembedded slides were deparaffinized through a series of xylene and ethanol washes. For ER immunoreactivity the following modified antigen-retrieval method was utilized: (1) 3% hydrogen peroxide to block endogenous peroxidases (8 min); (2) antigen retrieval in a microwave oven using a citrate buffer, pH 5.6-6.0 (twice for 7 min each); (3) normal horse serum (1:200) to block nonspecific protein binding (10 min); (4) I //g/ml anti-ER diluted 1:25 in 1% milk at 4°C overnight; (5) biotin-conjugated anti-mouse IgG 30 min at room temperature; (6) streptoavidin/horseradish peroxidase diluted 1:100 for 30 min; and (7) horseradish peroxidase substrate, aminoethyl carbazole, for the appropriate color development. Slides were counterstained with hematoxylin. The specificity of the immunostaining was demonstrated when tissues showed no reaction if the primary antiserum was replaced with normal mouse IgG or mouse serum.
Statistics. Each group consisted of 10-12 animals. Means ± SD were determined for each of the following quantitative end points: body, uterus, ovary, and adrenal and pituitary gland weights, serum estrogen levels, and length and stage of estrous cycle. The MTBE treatment group means were compared to control means by the unpaired, two-sided Student (test. Fisher's exact test was utilized to determine if mice exposed to MTBE produced an estrous cycle profile different from diat of controls. After determining that standard deviations were not equal in control and MTBE-exposed mice, Welch ANOVA analysis of variance was utilized to evaluate vaginal lavage data. A significance level of 0.05 was used for all analyses.
RESULTS

Body, Organ, and Relative Organ Weight
The body weights of all animals increased during the course of the experiment, but inhalation of MTBE vapors by B6C3F1 female mice for 4 and 8 months significantly decreased body weight gain as compared to air-exposed controls (Table 1) . At 4 months, MTBE-exposed mice demonstrated a 37% increase in body weight, while air-exposed controls had a 57% increase in body weight. After 8 months of treatment, MTBE-exposed mice demonstrated a 45% increase in body weight, while air-exposed controls had a 79% increase in body weight. There was a significant decrease in mean uterine weight (83%) and relative uterine weight at both 4 and 8 months (79 and 77%, respectively) relative to control mice. Likewise, MTBE exposure significantly decreased mean ovary weight at both 4 and 8 months (55 and 51%, respectively) and relative ovary weight at 4 and 8 months (48 and 46%, respectively) ( Table 1) . Mean pituitary and relative pituitary weights were significantly decreased at both time points. Pituitary weights decreased 44 and 31% at 4 and 8 months and relative pituitary weights decreased 32 and 20%, respectively (data not shown). No significant changes in adrenal or relative adrenal weight were found after exposure to MTBE (data not shown).
Vaginal Smears
Vaginal smears taken at necropsy demonstrated a significant difference in the stages of the estrous cycle in MTBEexposed mice as compared to control mice. After MTBE exposure for 4 and 8 months, there was a decrease in the percentage of mice in late proestrus and estrus stages and an increase in the percentage of mice in diestrus and early proestrus stages (Table 2) .
To further characterize differences in the estrous cycle, vagina] lavages were performed to determine the average length of the estrous cycle in mice exposed to MTBE for 8 months as compared to control mice. During the vaginal lavage evaluation period, all mice exhibited estrous cycles. There was a 52% increase in the mean number of days required to complete an estrous cycle after 8 months of MTBE exposure as compared to control mice. The increase in the length of the cycle was due to a significant increase in the mean number of days in both the estrus and the nonestrus stages (Fig. 1) . The mean number of days in estrus increased from 1.3 ± 0.1 days in control mice to 2.3 ± 0.3 days in MTBE-exposed mice, and the mean number of days in the nonestrous stages (diestrus, early proestrus, and late proestrus) increased from 2.9 ± 0.2 days in control mice to 4.2 ± 0.3 days in MTBE-exposed mice.
Uterus
Uteri from mice exposed to MTBE for 4 or 8 months had fewer cross sections of uterine ducts and glands, and glands appeared less tortuous than air-exposed control mice in the same stage of the estrous cycle (Fig. 2) . In H&E-stained sections the uteri from MTBE-exposed mice were similar to those from unexposed mice 5 and 9 months after ovariectomy (data not shown).
To determine if the decrease in uterine weight (Table 1 ) and number of uterine glands was accompanied by modulation in uterine DNA synthesis specific to a cell type, we immunohistochemically stained uterine sections from MTBE-exposed and control mice in the same stages of the estrous cycle for BrdU incorporation (Fig. 2, Table 3 ). Control mice had over 90% of luminal and glandular epithelial cell nuclei immunoreactive for BrdU. In control mice stromal and muscle cells had low immunoreactivity to BrdU (less than 5%) (Fig. 2) . In MTBE-exposed mice there was a decrease in DNA synthesis in luminal epithelial cells (LI of approximately 25%) and glandular epithelial cells (LI of approximately 50%) (Fig. 2, Table 3 ). Similarly, short-term exposure to MTBE for 3 or 21 days, which also significantly decreased uterine weight (Moser et al., 1996) , produced less DNA synthesis in luminal and glandular epithelium (LI of approximately 25 and 50%, respectively) (data not shown) than control mice of the same age. MTBE exposure did not alter incorporation of BrdU into the nuclei of stromal elements and muscle layers of the uterus. In ovariectomized mice, less than 25% of luminal and glandular epithelial nuclei incorporated BrdU (data not shown). Decreases in uterine DNA synthesis in MTBE-exposed mice were also seen when uterine sections were immunohistochemically stained for PCNA (data not shown).
Cervix and Vagina
In mice exposed to MTBE for 4 or 8 months, tubular glands in the cervix and vagina were less branched and had a decreased number of convolutions and epithelial layers. Similar but less dramatic decreases in branching and cell layers were found in H&E-stained cervices and vaginas of mice exposed to MTBE for 3 or 21 days (data not shown). In BrdU-stained cervices and vaginas of control mice, over 90% of suprabasal epithelia nuclei were immunoreactive. Generally all five to eight epithelial layers contained BrdU- immunoreactive cells in control mice (Fig. 3) . After 21 days of exposure to MTBE, the cervix and vagina had decreased BrdU immunoreactivity in the basal epithelial cells and adjacent suprabasal cell layers. In ovariectomized mice, a decreased incorporation of BrdU was found in all epithelial cell layers (data not shown). PCNA immunoreactivity was present only in nuclei of the basal-most cell layer regardless of treatment and did not vary with length of MTBE exposure (data not shown).
Ovary
Microscopic evaluation of H&E-, BrdU-, and PCNAstained (data not shown) ovaries from mice exposed to MTBE for 3 or 21 days or 4 or 8 months was not different from controls. Like control mice, follicles in all stages of development (primary, secondary, and mature) and corpus lutea were found in MTBE-exposed mice. Over 80% of granulosa cell nuclei in follicles, especially near the basal lamina, were immunoreactive for BrdU. Over 80% of theca interna cell nuclei of more advanced follicles were also immunoreactive for BrdU. Approximately 50% of luteal cell nuclei and less than 10% of interstitial cell nuclei stained for BrdU in both controls and MTBE-exposed mice (data not shown).
Adrenal Glands
Treatment of mice with MTBE for 4 or 8 months resulted in loss of the zona reticularis as compared to control airexposed mice (Fig. 4) . This change was not present in mice exposed to MTBE for 3 or 21 days or in ovariectomized mice. No differences from control were found in BrdU immunoreactivity of the adrenal cortex after MTBE exposure at any time point (data not shown).
Pituitary MTBE-exposed mice had an increased number of hyaline droplets in the pars intermedia of the pituitary as compared to air-exposed control mice. These droplets were immunoreactive for adrenal corticotrophin hormone (ACTH). No differences in the location or incorporation of BrdU in the pituitary were observed in MTBE-exposed mice relative to control mice (data not shown).
Serum Estrogen Levels
Since serum estrogen levels typically vary with the stage of the estrous cycle, we compared estrogen levels of control and MTBE-exposed mice in the same stage of the estrous cycle. No significant differences in circulating estrogen levels were found after MTBE exposure (data not shown).
Estrogen Receptor Competitive Binding Assay, Transient Transfection Assay, and Immunoreactivity
Some antiestrogens mediate their biological effects through binding to ER. However, antiestrogens can also be metabolized in vivo to derivatives that have an affinity for ER. Thus, we assayed the ability of not only MTBE but also two of its metabolites, tertiary butyl alcohol (TBA) and formaldehyde, to displace 17/3-[ 3 H]estradiol binding to recombinant human ER from baculovirus-infected insect cells (Brady et al., 1990) . The specific binding of estradiol to human estrogen receptor in vitro was not inhibited by MTBE (Fig. 5) or either of its major metabolites at concentrations from 10~" to 10~4 M (data not shown).
We also examined the effect of MTBE on ER activity in transiently transfected HepG2 cells. Since the HepG2 assay was done in intact cells in the presence of serum, it allowed us to evaluate not only activation of the ER but also translocation of the ER complex to the response element on the DNA in the presence of serum binding proteins. Treatment of HepG2 cells with MTBE alone did not induce estrogen receptor activity (Fig. 5b) . In addition, MTBE did not antagonize a maximally inducing dose of estradiol. We compared ER immunoreactivity of MTBE-exposed uteri, cervices, and vaginas to those of controls. Estrogen receptor immunoreactivity was localized exclusively within the nuclei of all cell types in the uterus, cervix, and vagina using monoclonal antibody. No differences were found in the location of ER immunoreactivity in the uterus, cervix, and vagina of MTBE-exposed mice as compared to controls. Epithelial cells of uterine glands stained most intensely for ER. Approximately 90% of glandular epithelial cells were immunoreactive for ER. Luminal epithelial cells were also immunoreactive for ER (90%), but the intensity was decreased as compared with glandular epithelial cells. The immunoreactivity of the myometrium was similar in intensity to that of glandular epithelial cells with approximately 50% of muscle cells immunoreactive. The percentage of immunoreactive cells was least in the stroma, although the intensity was comparable to that found in epithelial cells of uterine glands. In the cervix and vagina, approximately 90% of epithelial cells were immunoreactive for ER, and the intensity of the ER immunoreactivity in epithelial cells was similar to the immunoreactivity of the luminal epithelial cells of the uterus. In mice that had been ovariectomized for 5 or 9 months, the intensity and percentage of ER-immunoreactive cells in the glandular epithelia were similar to intact controls, but there was a decrease in ER immunoreactivity in uterine luminal, cervical, and vaginal epithelial cells and an increase in ER immunoreactivity in the stromal cells of the endometrium relative to intact controls.
DISCUSSION
We demonstrated that short-term and subchronic exposure to high doses of MTBE vapor produced a broad spectrum of responses that are consistent with endocrine modulation. These responses included decreased uterine, ovary, and pituitary weight; fewer and less coiled uterine glands; decreased number of epithelial layers in the cervix and vagina; decreased zona reticularis in the adrenal cortex; alterations in the stages and length of the estrous cycle; and more ACTH-immunoreactive droplets in the pituitary after MTBE exposure (Table 3) . These data support our hypothesis that the female mouse tumor response after chronic MTBE exposure was associated with and likely secondary to hormonal dysregulation.
Many of the MTBE-induced endocrine effects are suggestive of antiestrogenicity. We used the term antiestrogens as meaning chemicals that prevent estrogen from having an effect on estrogen-dependent target tissues. Consequently antiestrogens antagonize a variety of estrogen-dependent processes including uterine growth, increased DNA synthesis in the uterus, cervix, and vagina, and growth of estrogendependent tumors (Martin and Finn, 1968; Leroy etal., 1969; Finn and Martin, 1973; Gallo et ai, 1986; Umbreit el al, 1987; Astroff and Safe, 1988; Webster etal, 1988) . Animals exposed to antiestrogenic chemicals can be identified by changes observed by several experimental paradigms (Martin and Finn, 1968; Gallo el al., 1986; Umbreit et al, 1987) . Decreased uterine, ovary, and pituitary weight, fewer uterine glands, thinning of cervical and vaginal epithelial cell layers, and decreased cell proliferation in epithelial cells of the endometrium, cervix, and vagina after MTBE exposure are tissue-specific properties indicative of estrogen antagonism (Martin and Finn, 1968; Leroy etal, 1969; Finn and Martin, 1973; Gallo et al, 1986; Umbreit et al, 1987; Astroff and Safe, 1988; Webster et al., 1988) .
Changes in the structure and function of uterine tissue in No change "Osmotic pumps containing 16 mg BrdU/ml were implanted 3j days before necropsy. Paraffin-embedded sections were H&E-stamed or immunohistochemically stained for BrdU and examined microscopically. nonpregnant mice has been the "gold standard" assay used for detection of antiestrogenicity. This whole-animal assay incorporates the effects of metabolism, serum binding, and pharmacokinetics in examining antiestrogenic effects. Uterine changes are regulated by ovarian hormones, estrogen and progesterone (Conney et al, 1967) . Estrogen increases cell proliferation in luminal and glandular epithelial cells while progesterone shifts mitotic activity to stromal cells (Martin and Finn, 1968; Finn and Martin, 1973) . Decreased DNA synthesis only in uterine epithelial cells suggests that MTBE produced its effects through estrogen antagonism. Since estrogen is principally secreted by ovaries, similar findings in surgically ovariectomized mice are supportive of MTBE producing at least some of its hormonal modulatory effects through an antiestrogenic mechanism.
MTBE exposure increased the length of the estrous cycle. Although some antiestrogens produce anestrus, increased length of the estrous is also suggestive of antiestrogenicity (Leroy et al, 1969; Finn and Martin, 1973; Katzenellenbogen et al, 1979; Gallo et al, 1986; Umbreit et al, 1987; Romkes et al, 1987; Astroff and Safe, 1988; Webster et al, 1988) . Increased length of the estrous cycle could also be associated with MTBE-induced decreased body weight gain, anesthesia-like effects, or stress (Tannebaum, 1942; Martin and Finn, 1968; Barlow and Sullivan, 1982; Masoro, 1993; Masoro, 1995) .
Regulation of estrogen-sensitive tissues is primarily mediated by the interaction of estrogen with intracellular ER in target cells. Some chemicals with estrogen antagonistic effects such as ICI 164,384, TAT-59, and tamoxifen and its metabolite, 4-hydroxytamoxifen, compete with estradiol in vitro for binding to ER (Conney et al, 1967; Katzenellenbogen et al., 1979; Wakeling et al, 1990; Lerner and Jordan, 1993; Yuchi et al, 1994) . Competitive binding to the ER is not the only mechanism of antiestrogenicity since other chemicals such as TCDD and PCB77 produced antiestrogenic effects without binding to ER (Kociba et al., 1978; Romkes et al, 1987; Jansen et al, 1993) . MTBE, TBA, and formaldehyde did not compete with 17/?-estradiol for binding to ER. In addition, MTBE did not alter binding of the ER to the response element on the DNA or antagonize the interaction of estradiol with ER in transiently infected HepG2 cells (Fig. 5) . Furthermore, MTBE (like TCDD) did not decrease serum estrogen levels (Devito et al, 1993) . These data suggest that MTBE did not mediate its effects through the ER pathway, and MTBE may produce its antiestrogenic effects through a mechanism similar to that of TCDD.
Estrogen-sensitive tissues are composed of multiple cell types, and responses to estrogenic and antiestrogenic agents differ among cell types. To determine if MTBE produced differential responses in specific cell types and to corroborate the ER competitive binding assays, we immunohistochemically stained control, MTBE-exposed, and ovariectomized uteri, cervices, and vaginas for ER. In the present study we showed that uterus, cervix, and vagina were immunoreactive for ER, but the ovary lacked ER immunoreactivity. Recent studies indicated that ER/? but not ERa is localized to the ovary although autoradiographic studies demonstrated localization of [ 3 H]estradiol in granulosa cells of the ovary (Kuiper et al, 1996) . Ovariectomy did produce uterine, cervical, and vaginal cell-type specific modulation of ER immunoreactivity. However, similar changes in ER immunoreactivity were not seen in MTBE-treated mice.
The antiestrogen effects of MTBE could be due to increased hepatic catabolism of endogenous estrogen. Phenobarbital, TCDD, and other inducers of liver P450 enzymes inhibited estrogen-induced increases in uterine weight, possibly by increasing hepatic enzymes that metabolize endogenous estrogen (Levin et al, 1968; Gustafsson and IngelmanSundeberg, 1979) . MTBE also increased the activity of hepatic microsomal cytochrome P450 enzymes in mouse liver that metabolize 17/9-estrogen and significantly increased the catabolic capacity of hepatocytes (twofold) after pharmacological doses of 17/3-estradiol and the synthetic estrogen ethinyl estradiol (Kociba et al, 1978; Moser et al, 1996) . However, there were no changes in circulating serum estrogen levels, suggesting that MTBE elicited its antiestrogenic effects at the tissue level.
Regulation of estrogen levels and estrogen-sensitive tissues is a complex phenomenon controlled by multiple hormones and pathways. Estrogen secretion is contingent not only upon the functionality of the ovary but also upon the pituitary gonadotrophins, follicle-stimulating hormone (FSH) and lutenizing hormone (LH). The following findings suggest that MTBE did not disrupt the ovarian-pituitary axis. Normal circulating estrogen levels which closely paralleled ovarian follicular maturation and normal proliferation of the ovary in MTBE-exposed mice suggest the presence of FSH and LH and their functional receptors. Intact pituitary gonadotrophin-induced steroidogenesis is further supported by the presence of estrous cycles albeit increased length, corpus lutea, and normal litters in a two-generation study in rats (Neeper-Bradley et al., 1995) . Together these observations suggested that MTBE was not directly toxic to the ovary or pituitary in mice. Histological findings and attenuation of cell proliferation in epithelial cells of the uterus and cervix suggested that MTBE produced its effects directly on the uterus, cervix, and vagina. Since others have shown that After an overnight incubation, the receptor complex was precipitated with a HAP solution. The HAP pellets were washed three times, and the radioactivity in the pellets was determined, (b) Effect of estradiol or MTBE on estrogen receptor activity in transiently transfected HepG2 cells. HepG2 cells in 24-well tissue culture plates were transiently transfected with a plasmid encoding for the human estrogen receptor, an estrogen-responsive luciferase reporter plasmid, and a constituitively expressed /3-galactosidase reporter plasmid (to control for transfection efficiency). Transfected cells were treated with various doses of estradiol, MTBE, or MTBE plus 3 X 10~8 M estradiol for 24 h and then assayed for luciferase activity. Data are presented as percentage of control luciferase activity obtained from 1O~7 M estradiol for each experiment. Graph represents the average ± standard error from three separate experiments with triplicate wells for each dose stromal cells mediate changes in the microenvironment that induce epithelial cell proliferation (Astrahantseff and Morris, 1994) , the effect of MTBE on epithelial cells with and without stromal cells in culture or tissue slices could address the issue of uterine hyporesponsiveness and cell-type specific toxicity.
The adrenal and pituitary gland are endocrine-sensitive tissues that also secrete hormones. The loss of the zona reticularis in the adrenal cortex and presence of ACTHcontaining droplets in the pars intermedia are novel findings. ACTH produced by the posterior lobe of the pituitary gland stimulates the zona reticularis's production of the adrenal steoird, cortisol. Although cortisol had been demonstrated to inhibit estrogen-induced uterine weight increase in ovariectomized rats (Bitman and Cecil, 1967) , it is not known if the loss of zina reticualris in the adrenal gland and ACTH droplets in the pituitary gland contribute to MTBE-induced antiestrogenic effects.
MTBE in concentrations of up to 15% is added to many formulations of UG. After subchronic and chronic exposure UG produced effects similar to those produced by MTBE. UG vapor (1) increased mouse liver tumors in female mice (MacFarland et al, 1984; Standeven and Goldsworthy, 1994) ; (2) increased kidney tumors in male rats (MacFarland et al, 1984) ; (3) decreased uterine cystic hyperplasia after chronic exposure (MacGregor et al, 1993) ; (4) decreased uterus, pituitary, and ovary weight after 4 months of exposure (Standeven et al, 1994b) ; (5) increased the length of the estrous cycle (Moser et ai, 1997a) ; (6) increased hepatic estrogen catabolism in isolated hepatocytes from cycling mice (Standeven et ai, 1994a) ; (7) did not alter serum estrogen levels in cycling mice (Standeven et al, 1994b) ; and (8) did not competitively bind to the ER (Standeven et al, 1994b) . The UG-induced decrease in uterine, ovary, and pituitary weight and increased length of the estrous cycle were reversible upon removal of UG exposure (Moser et al., 1997b) (personal observation). MTBE-mediated hormonal modulations may also return to normal levels after cessation of exposure, suggesting tissue-reversible hyporesponsiveness as the basis of the observed hormonal-modulatory effects. The similar effects in hormone-responsive tissues and rodent tumor profiles in mice after UG and MTBE vapor exposure suggested that UG may be an endocrine modulator through a mechanism similar to that of MTBE.
Caloric restriction has been demonstrated to decrease uterine weight (Masoro, 1993) , pituitary weight (Koizumi et ai, 1992) , and incidence of mammary tumors (Tannebaum, 1942) and increase the length of the estrus cycle (Masoro, 1995) in mice. In these studies and after chronic exposure, MTBE-exposed mice gained less weight than controls. The decrease in body weight gain after MTBE exposure was mild as compared to the 75% decrease in body weight gain seen in food restriction studies (Tannebaum, 1942; Koizumi et al, 1992; Masaro, 1993) . Although we did not determine caloric consumption in MTBE-exposed mice, the decreased body weight suggested that decreased food intake may have been secondary to toxicity of MTBE. Dietary restriction can also mildly increase serum ACTH levels (Tannebaum, 1942) which are consistent with adrenalocorticoid-immunoreactive droplets in the pituitary. Despite these correlations we do not believe that the hormonal effects in MTBE-exposed mice were secondary to caloric restriction. No significant decreases in body weight were seen after 3 or 21 days of exposure to 8000 ppm MTBE (Moser et al, 1996) , after 18 months of exposure to 3000 ppm MTBE (Burleigh-Flayer et al, 1991) , or in ovariectomized mice (Moser et al, 1997b ), yet these exposure conditions produced alterations in hormone-sensitive tissues. In addition, we have demon-strated that chronic and subchronic exposure to unleaded gasoline vapor produced effects similar to those produced by MTBE without a loss in body weight (Staneven and Goldsworthy, 1994; personal observation) . These data indicate that some doses of MTBE as well as UG produced endocrine dysregulation without decreasing body weight.
In conclusion we have demonstrated that high levels of MTBE produced effects consistent with endocrine modulation. MTBE-induced endocrine changes were seen after exposure to high concentrations of MTBE that are generally not encountered in humans. The general public is routinely exposed to much lower concentrations-a maximum of 2.6 ppm in the area where customers or attendants pump gas and 0.2 ppm at the perimeters of gas stations (Anderson, 1993) . The relevance of the endocrine alterations we saw in mice exposed to high concentrations of MTBE for extended periods of time to human risk assessment is unknown. Since all of the MTBE-induced tumor sites are known to be mediated in part by the endocrine system, studies should be conducted investigating the role of MTBE-induced hormonal changes as a basis for all MTBE-induced tumor sites. Furthermore, both UG and MTBE produce similar endocrine effects in female mice. Given that many formulations of UG are supplemented with MTBE, studies should examine if the combination of MTBE and UG acts additively or synergistically to enhance the endocrine dysregulation produced by either agent alone.
